Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma
The purpose of this study is to determine whether ulipristal acetate is effective in the treatment of females with anemia associated with uterine leiomyomas. The safety of this product will also be evaluated.
Leiomyomas
DRUG: Ulipristal Acetate|DRUG: Iron
Change from baseline in hemoglobin levels (g/dL), Change from baseline in hemoglobin levels (g/dL), Day 1 of the first on-treatment menstrual cycle to the start, or scheduled start of menstrual cycle 3.
This is a randomized, placebo controlled, multicenter study with parallel groups in order to evaluate the efficacy and safety of ulipristal acetate in female subjects with anemia associated with uterine leiomyomas. The objective of this study is to determine if daily ulipristal acetate with iron is more effective than iron alone.